Late-breaking data demonstrate Abbott’s FreeStyle Libre® 3 System is more accurate 14-day continuous glucose monitor

Late-breaking data demonstrate Abbott's FreeStyle Libre® 3 System is more accurate 14-day continuous glucose monitor

Data at the American Diabetes Association 82nd Scientific Sessions shows that Abbott’s FreeStyle Libre® 3 system is the first and only 14-day continuous glucose monitor (CGM) system to achieve a mean absolute relative difference (MARD) of less than 8%.

MARD is considered the simplest measurement of sensor accuracy and represents the difference between a CGM system’s glucose readings and a reference blood glucose measurement. The lower the MARD, the more accurate the CGM system.

Additional data shows the positive impact of the FreeStyle Libre system and LibreView app in helping healthcare professionals make earlier treatment decisions and detecting hypoglycaemic events.

Mahmood Kazemi, M.D., divisional vice president, global medical affairs and chief medical officer of Abbott’s diabetes care business, said: “Abbott revolutionised glucose monitoring with our world-leading FreeStyle Libre technology — the first sensor to eliminate painful fingersticks by offering factory-calibrated continuous glucose monitoring that is affordable, accessible and accurate.

“A sub-8% overall MARD for the FreeStyle Libre 3 system is a significant milestone, not just in terms of CGM innovation, but because it empowers people with diabetes to be more confident when making important diabetes management decisions.”

The multi-center study evaluated the accuracy of the FreeStyle Libre 3 system in people with type 1 or type 2 diabetes, aged 4 or older, who were on insulin therapy. By age group, MARD values were 7.6% for adults (people ages 18 and up) and 8.7% for children ages 6-17.  For children aged 4-5 years old, MARD value was 10.1%.

Other notable findings presented at ADA:

FreeStyle Libre system helps prevent therapeutic inertia: Getting glycemic levels under control earlier can lead to better outcomes, including a reduction in long-term vascular complications. An analysis of retrospective data collected over 24 months from more than 370,000 patients with type 2 diabetes in Canada shows that insights from FreeStyle Libre data helped clinicians make earlier decisions or adjustments to type 2 diabetes treatments versus making decisions based on conventional blood glucose monitoring (BGM).
A comparative study suggests that new Glucose Pattern Insights report in LibreView helps primary care providers identify and treat hypoglycemia events that are missed when using standardized reports: Powered by LibreView, the Glucose Pattern Insights report is a new CGM-based tool that was developed to identify patterns of poor glycemic control and offer considerations for the clinician.

More than 133 million Americans currently live with diabetes or prediabetes, equivalent to nearly half of the U.S. population, according to the American Diabetes Association. Diabetes is also the most common underlying chronic condition in the U.S., with 1.4 million Americans aged 18 years or older newly diagnosed each year. Abbott is committed to innovating new tools and technologies to help people with diabetes achieve the best health outcomes possible.

Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 113,000 colleagues serve people in more than 160 countries.

Author: Eileen Gilbert